TOX: a potential new immune checkpoint in cancers by pancancer analysis

• DOI: 10.1007/s12672-024-01236-1
• Publication Date: 2024-08-16T17:01:45Z
• Authors: Shengliang Qiu; Weiye Lin; Zhengyang Zhou; Qianran Hong; Shuangyu Chen; Jiayang Li; Fengyun Zhong; Qinfeng Zhou; Dawei Cui
• Keywords: TOX; Cancer prognosis; Multiomics technologies; Research; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Immune checkpoint; Immunotherapy; RC254-282

Thymocyte selection-associated HMG-BOX (TOX) belongs to a family of transcription factors containing highly conserved region the high mobility group box (HMG-Box). A growing body research has shown that TOX is involved in occurrence and development tumors promotes T-cell exhaustion. We assessed role with The Cancer Genome Atlas (TCGA) Pancancer Data. expression was examined RNA-seq data from TCGA Genotype-Tissue Expression (GTEx) databases. genetic alteration status protein level were analyzed using databases, including Human Protein (HPA), GeneCards, STRING. prognostic significance estimated survival TCGA. Moreover, R software used for enrichment analysis TOX. relationship between immune cell infiltration Tumor Immune Estimation Resource (TIMER) 2.0 database "CIBERSORT" method. correlation checkpoints further explored. Immunohistochemical verify difference cancerous paracancerous tissues, viability evaluated CCK-8 assay. In most cancer types cohort, differential observed. examined, prognosis cancers associated expression. levels closely related different immune-related pathways, checkpoints. Additionally, significant differences several tissues validated. Furthermore, clearly impacted cells. TOX, potential biomarker cancer, may be regulation microenvironment can new targeted drugs.